Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease.

Key Points

• This research aims to evaluate fistula calprotectin (FiCP) as a biomarker for inflammation and treatment response in perianal fistulizing Crohn's disease.
• Evaluated the relationship between FiCP levels and local inflammatory activity.
• Assessed the dynamic tracking of treatment response using FiCP as a biomarker.
• FiCP levels correlated with local inflammation in perianal fistulizing Crohn's disease.
• FiCP effectively monitored treatment response, indicating its potential clinical utility.